Please assess the completion status of the following clinical trial:

Trial Title: Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AML in first remission~* cytological standard risk, i.e. karyotype not listed under exclusion criteria~* Identification of HLA-identical sibling or HLA-compatible related or unrelated donor (9/10 HLA-alleles matched, high resolution typing for HLA-A, B, Cw, DRB1 and DQB1)~* age: 18 - 60 years~* medically fit for allogeneic stem cell transplantation~* CR / CRi after induction therapy~Exclusion Criteria:~* core-binding factor leukemia (t(8;21), inv16)~* acute promyelocytic leukemia (t(15;17)~* complex aberrant karyotype~* karyotypes: -7; -5; del5q; t(3;3); t(6;11), t(6;9), 11q aberrations, trisomy 8 ± one single additional aberration~* pregnancy / nursing~* non-compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Human Stem Cell Transplantation (Type: EXPERIMENTAL): Patients receive an allogenic stem cell transplantation from an HLA-matched unrelated or related donor
- Consolidating Chemotherapy (Type: ACTIVE_COMPARATOR): Patients receive a standard chemotherapy as consolidation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).